Dear Colleagues, Welcome to my PES monthly President’s Newsletters! I want to begin by expressing my heartfelt gratitude to Dr.…
More Articles
In Memoriam: Delbert A Fisher, MD (August 12, 1928 – March 4, 2026) Del Fisher, MD, one of the 38 founding members of our Society (formerly the Lawson Wilkins Pediatric…
March Historical Tidbit – Then and Now: This Month in Endocrine History Submitted by Evan Graber, DO In March 1922, Banting and Best published a preliminary report on the effect of subcutaneously…
Sahaj Singh, MD I am Sahaj Singh, a second-year pediatric endocrinology fellow at Texas Children’s Hospital, Baylor College of Medicine. I am originally from India, where I began my medical…
New Drugs and Therapeutics Update: DESMODA™ (desmopressin acetate) Oral Solution Prepared by Daniel Mak, MD DESMODA® (desmopressin acetate) Oral Solution On February 25th, 2026, the FDA approved DESMODA™ (desmopressin acetate)…
Dear Colleagues, This winter is bringing lots of flurries, both of actual snow (16″ at my house this week on top of that remaining from the January storm) and of PES activities. Multiple education…
Karen L. Clark, MMSc, PA‑C Karen L. Clark, MMSc, PA‑C, is an Advanced Practice Provider with more than 20 years of experience in pediatric endocrinology at St. Jude Children’s Research…
February Historical Tidbit: Then and Now: This Month in Endocrine History Submitted by Evan Graber, DO In February 1985, Ullrich et al reported the amino acid sequence of the insulin receptor precursor. This allowed for elucidation of the function…
Rachael Mullin, DO, MS I am a third-year Pediatric Endocrinology fellow at Oregon Health & Science University (OHSU) in Portland, Oregon. Originally from Northern California, I earned my Bachelor…
Mounjaro (tirzepatide) approved in Pediatrics Prepared on behalf of PES Drugs and Therapeutics Committee by, Evan Graber, DO, Emily Breidbart, MD, and Neha Patel, DO. Based on results from the SURPASS-PEDS…
Depo-Provera and Increased Risk of Meningioma: FDA-Label Update. Written by: Anna Ryabets-Lienhard, DO as part of Drugs and Therapeutics Committee In December 2025, the U.S. Food and Drug Administration (FDA) approved…